Noile-Immune Biotech (TSE:4893) Altman Z2-Score: 61.63 (As of Jul. 05, 2026) — 12% Above Median


TSE:4893 Noile-Immune Biotech Inc TSE:4893
53 GF Score
Price 円128.00
GF Value 円4.36
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Altman Z2-Score?

Noile-Immune Biotech TSE:4893 +4.07% 53 Altman Z2-Score is 61.63 as of Jul. 05, 2026, which is 12% above its 10-year median of 54.95. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,391 Biotechnology companies, Noile-Immune Biotech ranks better than 98.85% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Noile-Immune Biotech has a Altman Z2-Score of 61.63, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Noile-Immune Biotech's Altman Z2-Score or its related term are showing as below:

TSE:4893' s Altman Z2-Score Range Over the Past 10 Years
Min: 17.78   Med: 54.95   Max: 69.25
Current: 54.18

During the past 6 years, Noile-Immune Biotech's highest Altman Z2-Score was 69.25. The lowest was 17.78. And the median was 54.95.


Noile-Immune Biotech  (TSE:4893) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Noile-Immune Biotech Altman Z2-Score Related Terms


Noile-Immune Biotech Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Altman Z2-Score Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 55.72 17.78 69.00 69.25 54.18

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.25 51.38 69.01 54.18 0.00

TSE:4893 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Noile-Immune Biotech's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Noile-Immune Biotech Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's Altman Z2-Score falls into.


TSE:4893
53GF Score
Noile-Immune Biotech Inc TSE:4893
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Noile-Immune Biotech's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.9769+3.26*-1.1186+6.72*-0.1464+1.05*57.0048
=61.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was 円3,844.79 Mil.
Total Current Assets was 円3,817.01 Mil.
Total Current Liabilities was 円61.05 Mil.
Retained Earnings was 円-4,300.67 Mil.
Pre-Tax Income was -152.827 + 0 + -170.91 + -239.192 = 円-562.93 Mil.
Interest Expense was 0 + 0 + 0 + 0 = 円0.00 Mil.
Total Liabilities was 円66.28 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3817.012 - 61.05)/3844.791
=0.9769

X2=Retained Earnings/Total Assets
=-4300.672/3844.791
=-1.1186

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-562.929 - 0)/3844.791
=-0.1464

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3778.507 - 0)/66.284
=57.0048

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Noile-Immune Biotech has a Altman Z2-Score of 61.63 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 61.63 mean?
Noile-Immune Biotech (TSE:4893) has a Altman Z2-Score of 61.63 as of Jul. 05, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Noile-Immune Biotech and its competitors. This is 12% above median its historical median of 54.95. Over the past decade, Noile-Immune Biotech's Altman Z2-Score has ranged from 17.78 to 69.25. According to the industry distribution chart, Noile-Immune Biotech ranks #16 out of 1391 companies in the Biotechnology industry, placing it in the top 1.2%.
Is Noile-Immune Biotech's Altman Z2-Score too high?
Noile-Immune Biotech's current Altman Z2-Score of 61.63 is 12% above median its 10-year median of 54.95. Over the past 10 years, this metric has ranged from a low of 17.78 to a high of 69.25. Based on the distribution chart, Noile-Immune Biotech ranks #16 out of 1391 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #16 out of 1391 companies for Altman Z2-Score. This places Noile-Immune Biotech in the top 1% of its industry — outperforming the majority of peers. Historically, Noile-Immune Biotech's own Altman Z2-Score has ranged from 17.78 to 69.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Altman Z2-Score is 61.63, which is 12% above median its own 10-year median of 54.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円128.00 — trading 2835.8% above its estimated fair value. The current Altman Z2-Score is 61.63, which is 12% above median its 10-year median of 54.95. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Altman Z2-Score is 61.63 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円128.00 is trading 2835.8% above its estimated GF Value™ of 円4.36. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Altman Z2-Score: 61.63 (12% above median its 10-year median of 54.95)
  • GF Value™: 円4.36 vs. price of 円128.00 (2835.8% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score

Get the complete analysis for TSE:4893

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円128.00
Price
円4.36
GF Value